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The cyclic AMP sensor, EPAC1, activates AP1-mediated transcription in HUVECs. Correspondingly,
induction of the SOCS3 minimal promoter by EPAC1 requires a single AP1 site that constitutively
binds phosphorylated (Ser63) c-Jun in DNA-pull-down assays. c-Jun (Ser63) becomes further phos-
phorylated following cyclic AMP stimulation and speciﬁc activation of protein kinase A (PKA), but
not through selective activation of EPAC1. Moreover, despite a requirement for c-Jun for SOCS3
induction in ﬁbroblasts, phospho-null c-Jun (Ser63/73Ala) had little effect on SOCS3 induction by
cyclic AMP in HUVECs. AP1 activation and SOCS3 induction by EPAC1 in HUVECs therefore occur
independently of c-Jun phosphorylation on Ser63.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introduction
Elevations in intracellular cyclic AMP in response to activation
of adenosine and prostaglandin receptors in human umbilical vein
endothelial cells (HUVECs) leads to inhibition of interleukin 6 (IL-
6) signalling complex activation of STAT3 transcription factors
and the mitogen-activated protein (MAP) kinase, ERK [1]. This inhi-
bition occurs independently of the classical route for cyclic AMP
signalling, through protein kinase A (PKA), but is rather dependent
on the induction of the suppressor of cytokine signalling 3 (SOCS3)
gene in response to activation of exchange protein activated by
cyclic AMP (EPAC) 1 [1]. SOCS3 is an E3 ubiquitin ligase component
that targets IL6 signalling components for proteolytic degradation
[2], whereas EPAC1 is a speciﬁc guanine nucleotide exchange factor
(GEF) for the Ras GTPase homologues Rap1 and Rap2, which EPAC1
activates independently of PKA [3]. Cyclic AMP binding sites in
EPAC proteins facilitate their direct activation by cyclic AMP, there-
by relieving auto-inhibitory inﬂuences of the cyclic nucleotide
binding domain (CNBD) toward the catalytic GEF domain [3].
Recent research now implicates EPAC1 in the regulation ofmultiple inﬂammatory processes in vascular endothelial cells, like
HUVECs, including regulation of endothelial cell–cell junction sta-
bility [4] and activation of integrins [5], reduction in endothelial
permeability and down-regulation of IL-6-mediated inﬂammatory
processes [1]. The involvement of EPAC1 in the activation of multi-
ple protective mechanisms in one cell type highlights the impor-
tance of EPAC1 for the proper functioning of VECs and presents
an intriguing model by which distinct cellular processes interact
to initiate a co-ordinated program of protective, anti-inﬂammatory
events.
Given the importance of EPAC1 in limiting pro-inﬂammatory
IL6 signalling, we have begun to further delineate the molecular
basis of how elevations in intracellular cyclic AMP positively
control the expression of the SOCS3 gene. Our initial ﬁndings
implicated mobilisation of CCAAT enhancer binding protein (C/
EBP) transcription factors, C/EBPb and C/EBPd, which are sufﬁcient
to induce SOCS3 gene induction in HUVECs following EPAC1
activation [6]. Although EPAC1 activation is sufﬁcient to induce
SOCS3 expression in HUVECs, maximal SOCS3 gene expression also
requires supporting activity from the MAP kinases, ERK and JNK
[7,8]. In this case ERK is activated by cyclic AMP, independently
of both PKA and EPAC1 [7], and this is required for the
phosphorylation and activation of multiple transcription factors
associated with the SOCS3 promoter, including C/EBPb (Thr235),
STAT3 (Ser727) and SP3 (Ser73) [9]. JNK activation is also
promoted by cyclic AMP and principally leads to activation of the
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lation on Ser63 [8]. In light of recent reports implicating EPAC pro-
teins as regulators of JNK activity in diverse cell types [10,11], here
we address whether EPAC1 is involved in a similar regulation of
AP1 activity through c-Jun phosphorylation in HUVECs.
2. Materials and methods
2.1. Materials
Primary antibodies to total c-Jun, total STAT3, phospho-STAT3
(Tyr705), phospho-c-Jun (Ser63) and anti-b-tubulin were
purchased from New England Biolabs. Anti-SOCS3 antibody was
from Santa Cruz Biotechnology. Secondary antibodies, anti-rabbit,
anti-goat and anti-mouse IgG conjugated with horse radish perox-
idase (HRP), were purchased from GE Healthcare. Forskolin, rolipram
and MG132 were purchased from Merck/Calbiochem. 8-(4-Chlor-
ophenylthio)-20-O-methyladenosine-30, 50-cyclic monophosphate
(007) and N6-Benzoyladenosine-30, 50-cyclic monophosphate
(6-Bnz) were purchased from Biolog, Bremen, Germany. Recombi-
nant human interleukin 6 (IL-6) and soluble IL6 receptor (sIL-6Ra)
were bought from R&D Systems Europe Ltd. (Abingdon, UK).
2.2. Plasmids
The AP1 reporter construct (pMN34, containing 7 AP1 repeats)
was provided by Professor Walter Kolch (University College
Dublin, Republic of Ireland). Mouse SOCS3 promoter constructs
were a generous gift from Professor Johannes Bode (Heinrich-
Heine University, Dusseldorf, Germany) with permission from
Professor Shlomo Melmed (Cedars-Sinai Medical Centre, Los
Angeles, USA). These included pGL3-SOCS3-159 Luc, which
contains the promoter region 159 to +929 of the murine SOCS3
gene fused to the coding region of ﬁreﬂy luciferase as described
previously [12], as well as promoter truncates -107Luc, -79Luc,
-68Luc, and -49Luc and pGL3-SOCS3-107Luc constructs mutated
to disrupt the putative AP1 site as described [9]. Plasmids
(pcDNA3) expressing wild type human c-Jun or phospho-null
mutant, c-Jun (Ser63/73Ala), were generous gifts from Professor
Christopher Hughes (University of California Irvine, USA).
2.3. Luciferase assays
Human umbilical vein endothelial cells (HUVECs) were grown
in human endothelial cell growth medium 2 (PromoCell
Heidelberg, Germany) at 37 C in humidiﬁed 5% (v/v) CO2. Cultures
of 80–90% conﬂuent HUVECs in 12-well culture clusters were
transfected with 0.125 lg Renilla Luciferase reporter construct
(pGL4.74) plus 1.125 lg of murine SOCS3-Luc promoter constructs
using Lipofectamine 2000 (Life Technologies, UK). Transfected cells
were then incubated with treatments overnight at 37 C and
luciferase assays carried out the next day using the Promega Dual
Luciferase Reporter Assay System, according to the manufacturer’s
protocols. Luciferase activities were measured using a BMG
Labtech luminometer. Mouse embryo ﬁbroblasts (MEFs) from wild
type and c-Jun/ (KO) mice were provided by Professor David
Gillespie (Beatson Institute of Cancer Research, Glasgow, Scotland)
and cultured as described [13].
2.4. c-Jun transfection and immunoblotting
HUVECs were grown to 80–90% conﬂuence and then transfected
with human c-Jun or c-Jun (Ser63/73Ala) using Lipofectamine 2000
according to the manufacturer’s instructions. Cell lysates were
then prepared in sample buffer (50 mM Tris–HCl, pH 6.8,
2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) b-Mercaptoethanol,12.5 mM EDTA, 0.02% (w/v) bromophenol blue, 100 mM DTT).
Protein samples were then separated by SDS–PAGE on 10% (w/v)
gels and then transferred to nitrocellulose membranes. These were
blocked for 1 h at room temperature in 5% (w/v) BSA and then
immunoblotted with antibodies speciﬁc for SOCS3, tubulin, total
c-Jun, STAT3 and phospho-STAT3 (Tyr705) and visualised using
ECL chemiluminescence protocols (GE Healthcare).
2.5. DNA pull-down assays
Biotin-modiﬁed oligonucleotides were synthesised (Yorkshire
Biosciences) that corresponded to proximal promoter sequences
from the human SOCS3 gene that include putative AP1 and STAT
transcription factor binding sites (Fwd 50-CGAGTAGTGACTAAACA
TTACAAGA and Rev 50-TCTTGTAATGTTTAGTCACTACTCG) or with
the AP1 site disrupted (Fwd 50-CGAGTAAAGCTTAAACATTACAAGA
and Rev 50-TCTTGTAATGTTTAAGCTTTACTCG). Double-stranded
oligonucleotides were prepared by mixing equal amounts of for-
ward (biotin-labelled) and reverse oligonucleotide at 100 C for
1 h and then slow cooling to room temperature (30 min). Nuclear
extracts were isolated from stimulated HUVECs using a Nuclear Ex-
tract Kit (Active Motif). Protein concentrations in nuclear extracts
were normalised following Bradford assay, and then DNA pull-
down experiments using biotinylated probes were performed as
previously described [14]. Oligonucleotides were recovered using
streptavidin-agarose beads, which were then boiled in Laemmli
sample buffer and analysed by immunoblotting.
2.6. Statistics
Data was analysed using one-way analysis of variance (ANOVA)
with a Tukey–Kramer post-test.
3. Results
We previously found that EPAC1 activation by cyclic AMP in hu-
man umbilical vein endothelial cells (HUVECs) leads to mobilisa-
tion of C/EBP transcription factors and up-regulation of the gene
encoding suppressor of cytokine signalling 3 (SOCS3) [6]. Since
SOCS3 induction occurs independently of the classical route of cyc-
lic AMP-mediated transcription, namely the phosphorylation of
CREB by PKA [15], this represents a novel mechanism for cyclic
AMP-mediated transcription. Intriguingly, we recently found that
elevations in cyclic AMP in HUVECs also leads to the activation of
JNK MAP kinase, which also appears to be a requirement for SOCS3
transcription [8]. However the mechanisms underlying this remain
unclear. Normally JNK activates the oncoprotein c-Jun through
phosphorylation on Ser 63 and Ser73, leading to activation of the
activator protein-1 (AP1) transcription factor complex as a
homodimer, or as a heterodimer with Fos [16]. With this in mind
we investigate here whether c-Jun and AP1 contribute to the regu-
lation of SOCS3 induction in response to cyclic AMP in HUVECs.
In order to test whether cyclic AMP and EPAC1 activation leads
to activation of AP1 transcription factors, we transfected HUVECs
with a luciferase gene reporter construct expressing multiple cop-
ies of the AP1 transcription factor binding motif, and then stimu-
lated cells with the EPAC-speciﬁc cyclic AMP analogue, 8-pCPT-2
-O-Me-cAMP (007), the PKA-speciﬁc agonist, 6-Bnz (10 lM and
500 lM), or a combination of the adenylate cyclase activator for-
skolin and the cyclic AMP-speciﬁc phosphodiesterases inhibitor,
rolipram, (F/R). As a positive control cells were also stimulated
with the phorbol ester, phorbol 12-myristate 13-acetate (PMA),
which is a well-known activator of AP1 [17]. In these experiments
007 served as a speciﬁc activator of the EPAC1 isoform, since
EPAC2 is not expressed in HUVECs [7]. Moreover, we chose to
stimulate cells with forskolin in combination with the PDE4
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IBMX, because PDE4s have been shown to be intimately linked
with the regulation of EPAC1 in HUVECs [18]. We found that sim-
ilar to PMA, both 007 (10 lM) and F/R provoked a signiﬁcant
induction of AP1 activity with, surprisingly, 10 lM 007 provoking
an activation of AP1 which was signiﬁcantly greater than that
induced by F/R treatment (Fig. 1a). In contrast, stimulation with
10 lM 6-Bnz did not promote a signiﬁcant increase in AP-1 activity
and it was only until a concentration of 500 lM 6-Bnz was applied
that a signiﬁcant effect was observed, which suggests an off-target
effect of 6-Bnz at high concentrations. Together, these results
suggest that AP1 activity is exquisitely sensitive to EPAC1, and
not PKA activation in HUVECs.
We have previously shown that transcriptional activation of
SOCS3 in COS1 cells in response to PMA treatment requires anFig. 1. EPAC1 activation promotes AP1-dependent transcription of the SOCS3 gene in H
then stimulated with the EPAC-speciﬁc agonist 007 (10 lM), the PKA-speciﬁc agonist 6-B
activator forskolin (10 lM) and the cyclic AMP-speciﬁc phosphodiesterase inhibitor roli
then prepared and luciferase activities measured as described in Section 2. Signiﬁcant d
signiﬁcant increases in 007-treated cells compared to those treatment with 6-Bnz or F/
deletions and truncations of the murine SOCS3 promoter. Cells were then stimulated f
luciferase activity. Signiﬁcant differences relative to diluent-treated cells are indicated,
cells, ###P < 0.001 (n = 3). (c) HUVECs were transfected with the minimal murine SOCS3 p
Cells were then stimulated with either 6-Bnz (500 lM) or 007 (10 lM). Cell extracts we
treated cells are indicated ⁄⁄⁄P < 0.001; as are signiﬁcant differences relative to 007-tr
###P < 0.001 (n = 3).AP1, a distal STAT, a proximal STAT and an SP3 transcription factor
binding site, all of which are found within the minimal SOCS3 pro-
moter [9]. We therefore transfected HUVECs with luciferase repor-
ter constructs containing deletions of the murine SOCS3 promoter
where the individual AP1, STAT and SP3 DNA binding sites had
been removed sequentially (Fig. 1b). Transfected cells were then
stimulated with F/R or 007 and luciferase activities determined.
We found that F/R treatment provoked activation of minimal pro-
moter construct containing all four transcription factor binding
sites. However, the combined deletion of the AP1 and distal STAT
sites abolished the response to F/R treatment (Fig. 1b), and also
to 007 treatment (Fig. 1b, lower panel). Moreover, individual
ablation of the AP1 site alone was sufﬁcient to ablate the response
of the minimal SOCS3 promoter to both 007 and F/R treatment
(Fig. 1b, lower panel). In contrast, we found that induction of theUVECs. (a) HUVECs were transfected with an AP1 luciferase reporter construct and
nz (at either 10 lM or 500 lM, as indicated), a combination of the adenylate cyclase
pram (10 lM), or the protein kinase C activator, PMA (100 nM). Cell extracts were
ifferences relative to diluent-treated cells are indicated, ⁄⁄⁄P < 0.001 (n = 3), as are
R, ###P < 0.001. (b) HUVECs were transfected with luciferase constructs containing
or 16 h with either F/R or 007 (lower panel). Cells extracts were then assayed for
⁄⁄⁄P < 0.001, as are signiﬁcant decreases in luciferase activity relative to F/R-treated
romoter or the minimal promoter with disruptive deletions in the putative AP1 site.
re then assayed for luciferase activity and signiﬁcant differences relative to diluent-
eated cells transfected with minimal promoter vs. with AP1-mutated constructs,
Fig. 2. Activation of PKA, but not EPAC1, promotes AP1-associated c-Jun activation
in HUVECs. HUVECs were stimulated for 5 h with either 007 (10 lM), the PKA-
activator, 6-Bnz (10 lM), or F/R. Nuclear extracts were then prepared and
precipitated with the biotinylated oligonucleotides detailed in the upper panel.
Cell extracts (input) and precipitated proteins were then Western blotted with the
indicated antibodies. Results are representative of an experiment carried out on
three separate occasions and densitometic analysis of multiple immunoblots is
displayed as a histogram in the lower panel as the ratio of pJun (Ser 63) to total Jun
immunoreactivity. Signiﬁcant differences relative to diluent-treated cells are
indicated, ⁄⁄⁄P < 0.001, as is the signiﬁcant decrease in immunoreactivity in samples
from 6-Bnz-treated cells relative to F/R-treated cells, ###P < 0.001 (n = 3).
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(500 lM) was not affected by deletion of the AP1 site, indicating
that at these concentrations 6-Bnz acts independently of AP1 to in-
duce SOCS3 expression (Fig. 1c). We also found that, unlike 007,
lower concentrations of 6-Bnz (10 lM) were unable to induce acti-
vation of the SOCS3 minimal promoter (results not shown).
Together, these results suggest that induction of SOCS3 transcrip-
tional activity following EPAC1 activation, but not PKA activation,
requires a distinct AP1 site within the SOCS3 minimal promoter
in HUVECs. It should be noted that in Fig. 1 007 produces an acti-
vation of the AP1 reporter that is greater than that induced by F/R.
In contrast, in Fig. 1b (lower panel), F/R is more effective than 007
at inducing induction of the SOCS3 minimal promoter. This is prob-
ably due to the fact that F/R activates a range of transcription fac-
tors to induce SOCS3 gene expression [8,9], through the activation
of ERK and JNK MAP kinase pathways [8,9], whereas SOCS induc-
tion in response to 007 appears only to require induction of AP1
activity. This may help explain why the SOCS3 promoter is more
responsive to F/R treatment and why AP1 activity is more sensitive
to stimulation with 007 than with F/R.
Given that the transcription factor c-Jun is a constituent of AP1
homodimers and heterodimers, we next determined whether c-Jun
associates with the putative AP1 binding site in the SOCS3 minimal
promoter and whether it becomes activated following EPAC1 or
PKA activation. We therefore synthesised two biotinylated DNA
probes corresponding to the section of the SOCS3 promoter con-
taining the putative AP1 and distal STAT binding sites (SOCS3
WT; Fig. 2). We also synthesised a corresponding DNA probe where
the AP1 site had been disrupted by targeted substitution of nucle-
otides in the consensus AP1 binding site (SOCS3 DAP1; Fig. 2). The
two biotinylated probes were then used in DNA pull-down assays
with nuclear extracts from HUVECs that had been stimulated with
either 007 (10 lM), the PKA-speciﬁc cyclic AMP analogue, 6-Bnz
(10 lM) or F/R (Fig. 2). DNA precipitates were then immunoblotted
with antibodies that recognise c-Jun phosphorylated on the JNK-
target site, Ser 63 (pc-Jun (Ser 63)), or antibodies that recognise
either total c-Jun or STAT3 proteins. Results indicated that STAT3
associated with both the SOCS3 WT DNA and SOCS3 DAP1 probes,
and levels remained unchanged following stimulation (Fig. 2). In
contrast, whereas c-Jun was seen to associate with the SOCS3
WT in a partially active form, as indicated by the lower mobility
of probe-associated c-Jun protein and positive staining with the
pc-Jun (Ser63) antibody, little pc-Jun (Ser63) immunoreactivity
was seen to associate with the SOCS3 DAP1 probe (Fig. 2). Despite
this, a corresponding reduction in total c-Jun immunoreactivity
associated with the SOCS3 DAP1 probe meant that the ratio of
pc-Jun (Ser 63):total c-Jun was relatively unchanged (Fig. 2; lower
panel). However, the appearance of a high molecular weight form
of total c-Jun associated with the SOCS3 DAP1 probe (Fig. 2; upper
panel), which might represent an inactivated, hyper-phosphory-
lated form of c-Jun [8], indicates that although the relative level
of Ser63 phosphorylation is unchanged following disruption of
the SOCS3 AP1 site, most of the probe-associated c-Jun is in an
inactive form. Together, these results suggest that the putative
AP1 binding site in the SOCS3 minimal promoter has the ability
to interact with active c-Jun. Moreover, activation of EPAC1 with
007 had essentially no effect on the amount of active, Ser63-phos-
phoryted c-Jun associated with the SOCS3 AP1 site. However acti-
vation of PKA with 6-Bnz-cAMP (10 lM), or activation of both
EPAC1 and PKA with F/R, lead to an increase in the amount of
pc-Jun (Ser63) associated with the SOCS3 WT probe (Fig. 2). This
suggests that cyclic AMP-stimulated phosphorylation and
activation of c-Jun associated with the SOCS3 promoter requires
PKA, but not EPAC1.
These results raise the question as to the requirement for c-Jun
in the control of SOCS3 induction in response to elevations inintracellular cyclic AMP. We previously demonstrated that the
transcription factors C/EBPb and C/EBPd are both required and
sufﬁcient for induction of the SOCS3 gene in HUVECs following
EPAC1 activation [19]. We therefore examined whether the same
is true for c-Jun. We therefore transfected HUVECs with cDNAs
encoding wild type human c-Jun (c-Jun WT) or human c-Jun,
where Ser63 and Ser73 had been mutated to alanine (c-Jun AA;
Fig. 3a). Cells were then stimulated with F/R, in the presence or
absence of the proteasome inhibitor, MG132, to inhibit proteolytic
digestion of SOCS3 protein following its synthesis, thereby
stabilising its expression, as described [1]. We found that F/R
provoked a robust induction of SOCS3 protein in the presence
of MG132, which was unaffected by transfection of cells with
Fig. 3. c-Jun is required, but not sufﬁcient, to promote SOCS3 induction by cyclic AMP. (a) HUVECs were transfected with vectors expressing human c-Jun or c-Jun where
Ser63 and Ser73 had been converted to alanine (Ser63/73Ala). Cells were then stimulated with F/R (5 h) in the presence or absence of the proteasome inhibitor MG132 to
stabilise SOCS3 expression. Cell extracts were then immunoblotted with the indicated antibodies and denstitometric values are displayed as a histogram in the lower panel.
Signiﬁcant increases in SOCS3 immunoreactivity relative to diluent-treated cells are shown, ⁄P < 0.05 and ⁄⁄⁄P < 0.001, as is the signiﬁcant in increase in immunoreactivity in
F/R + MG132 cells relative to cells treated with MG132 alone (###P < 0.001, n = 3). (b) HUVECs were transfected with wild type human c-Jun or mutant c-Jun (Ser63/73Ala),
and then stimulated with combinations of F/R and IL6 for 5 h as indicated. Cell extracts were then immunoblotted with antibodies that recognise c-Jun, total STAT3 and STAT3
phosphorylated on Tyr705. Densitometric analysis of immunoblots was carried out and results are presented as a histogram in the lower panel. Signiﬁcant increases in
pSTAT3 (Tyr 705) immunoreactivity relative to diluent-treated cells are shown, ⁄⁄⁄P < 0.001, as are signiﬁcant decreases in immunoreactivity in c-Jun transfected cells, relative
to mock-transfected cells (###P < 0.001, n = 3). (c) Wild type or c-Jun knockout mouse embryonic ﬁbroblasts (MEFs) were transfected with or without (mock) c-Jun or c-Jun
(Ser63/73Ala) and then stimulated in the presence or absence of F/R (5 h) plus MG132, as indicted. Cells extracts were then prepared and immunoblotted with the indicated
antibodies. Densitometric values from immunoblots are displayed in the lower panel where signiﬁcant increases in SOCS3 immunoreactivity relative to diluent-treated cells
are shown, ⁄⁄⁄P < 0.001 (n = 3).
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that over-expression of both c-Jun WT or c-Jun AA enhanced
the ability of F/R to suppress IL6-promoted STAT3 phosphoryla-
tion in HUVECs (Fig. 3b). Finally, to test whether c-Jun is
required for cyclic AMP-induced SOCS3 expression we used
mouse embryonic ﬁbroblasts (MEFs) from wild type mice and
animals where both alleles for c-Jun had been deleted (KO;
Fig. 3c). We found that in the presence of MG132, F/R stimula-
tion of WT cells led to a robust induction of SOCS3 expression,
which was completely ablated in c-Jun KO MEFs (Fig. 3c).
Moreover, transfection of c-Jun KO MEFS with either c-Jun WT
or c-Jun AA cDNAs rescued the ability of F/R to induce SOCS3
expression (Fig. 3c). Together these results indicate that c-Jun
is required, but alone insufﬁcient, to induce SOCS3 gene expres-
sion in response to elevations in intracellular cyclic AMP.
4. Discussion
The principle ﬁndings of this study are that EPAC1 induces acti-
vation of AP1-mediated transcription and that AP1 is a require-
ment for the induction of the SOCS3 gene by EPAC1 in HUVECs.
Our work also shows that the principle AP1 component, c-Jun,
although required for SOCS3 induction by cyclic AMP in MEFs
(Fig. 3c), is not sufﬁcient for SOCS3 induction in HUVECs
(Fig. 3a). This is in contrast to C/EBP transcription factors that are
absolutely required and sufﬁcient for SOCS3 induction in response
to EPAC1 activation in HUVECs [6]. This suggests that c-Jun may
therefore play a supporting role in controlling the activation of
the SOCS3 promoter in response to C/EBP activation. In this
respect, it has been reported that c-Jun can form heterodimers
with C/EBP isoforms that promote the transcription of the PU.1
promoter during monopoiesis [20]. Whether similar Jun/C/EBP
dimers regulate SOCS3 induction in HUVECs remains to be
determined.
With regards to cyclic AMP-dependent c-Jun phosphorylation
on the SOCS3 promoter, this appears to be regulated through
PKA-, rather than EPAC1-dependent mechanisms, since the PKA-
selective agonist 6-Bnz (10 lM), but not 007, was able to promote
Ser63 phosphorylation in DNA-pull-down assays (Fig. 2). More-
over, although PKA can promote phosphorylation of Ser63, this
phosphorylation appears to be dispensable for the induction of
SOCS3 expression in both HUVECs (Fig. 3a) and MEFs (Fig. 3c).
Accordingly, AP1 activation and SOCS3 promoter induction was
only promoted by 500 lM 6-Bnz in HUVECs (Fig. 1a and c). To-
gether, this indicates a PKA-independent mode of action of cyclic
AMP on AP1-dependent SOCS3 induction and suggests that for
EPAC1 to induce SOCS3 expression it must either activate c-Jun
through Ser63-independent mechanisms or promote dimerization
of c-Jun with another active component of the AP-1 complex, such
as c-Fos [21] or C/EBP isoforms [20]. Intriguingly, although c-Jun is
not sufﬁcient to induce SOCS3 expression in HUVECs, it is sufﬁcient
to suppress IL6 signalling to STAT3 activation (Fig. 3b). This sug-
gests that c-Jun may play a wider, SOCS3-independent, role in
the control of anti-inﬂammatory signalling in HUVECs. Overall
we describe new mechanisms by which EPAC1 can regulate
transcription in HUVECs through the control of AP-1 transcription
factors, in a PKA-independent manner. This control appears not to
involve the classical route of JNK-mediated phosphorylation of
c-Jun and may therefore involve cooperation between c-Jun and
other transcription factors, such as C/EBPs. This remains to be
formally tested.Acknowledgements
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